Gradient Denervation Technologies
France - ParisBiotechnology
Focus: Gradient Denervation Technologies is a France-based biotechnology company developing a denervation device system for cardiovascular and pulmonary hypertension indications. The company operates as a pre-revenue biotech with a focused device pipeline targeting heart failure and pulmonary hypertension patients.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Gradient Denervation Technologies
AI assessmentNot HiringNo open roles listed right now. Follow Gradient Denervation Technologies to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Gradient Denervation System
Pulmonary HypertensionClinical Trials (1)
NCT06495970Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)
N/AHelp build intelligence for Gradient Denervation Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.